IC50: 0.78 μM (neuroprotection)[1]
(Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model[1][2].
(Arg)9 (Nona-L-arginine; 5-10 μM) acetate provides significant neuroprotection in a dose-response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 acetate is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 acetate also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].
(Arg)9 (Nona-L-arginine; 1 μM/kg (600 μL); i.v.; once, for 30min; male Sprague-Dawley ratspermanent middle cerebral artery stroke model) acetate shows neuroprotective effects and reduces infarct volume[2].
| Animal Model: | Male Sprague-Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model[2] |
| Dosage: | 1 μM/kg (600 μL) |
| Administration: | Intravenous injection; once, over 5 minutes |
| Result: | Reduced significantiy 20% in infarct volume. |